{"created":"2021-03-01T06:19:10.877408+00:00","id":14723,"links":{},"metadata":{"_buckets":{"deposit":"a1d546cd-7791-4f49-890c-3cc7ae6977b1"},"_deposit":{"id":"14723","owners":[],"pid":{"revision_id":0,"type":"depid","value":"14723"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00014723","sets":["453:456","471:537:538:1071"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Phase I Dose Escalation Study of Multicyclic, Dose-Intensive Chemotherapy with Peripheral Blood Stem Cell Support for Small Cell Lung Cancer"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2001-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageEnd":"437","bibliographicPageStart":"432","bibliographicVolumeNumber":"115","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion of peripheral blood stem-cells (PBSCs) was conducted to determine the maximum-tolerated dose (MTD) of ICE. Twenty-seven patients with SCLC (LD : 9, ED : 18) were treated with ifosfamide (3000-9000mg/m^2, 24-hour-infusion), carboplatin (300-400mg/m^2), and etoposide (300mg/m^2) followed by subcutaneous injection of filgrastim (75μg/day) through day 4 to the day of PBSC collection. PBSC were harvested when the WBC count reached ≧5×10^9/L. The leukapheresis product was cryopreserved and reinfused on day 4 of the next cycle, which was started 48 hours after the last PBSC collection. The ifosfamide dose was escalated as follows : 3000mg/m^2 (level 1), 5000mg/m^2 (level 2), 7000mg/m^2 (level 3), 9000mg/m^2 (level 4). Patients with LD were treated with concurrent radiotherapy at 1.5 Gy twice daily for the initial 3 weeks to a total dose of 45Gy and MTD, defined separately. Patients were evaluated for hematologic and non-hematologic toxicity, actual dose intensities, as well as response to the therapy. The maximum-tolerated dose (MTD) was defined as the dose level at which the level produced more than 5 days of grade 4 myelosuppression or non-hematologic toxicity greater than grade 3 in two thirds of the patients. For ED cases, MTD was level 4 and the recommended dose of ifosfamide was 7000mg/m^2. For LD cases, the recommended dose of ifosfamide was 5000mg/m^2. The dose limiting toxicity of multicyclic ICE was hematologic toxicity and CNS toxicity which manifested as ataxia. Tumor responses were seen in all patients, with 14 patients showing a complete response. The actual total dose-intensity at the recommended dose level was 2.2 and 1.74, for ED and LD, respectively, compared with previously reported ICE regimens. PBSC support for dose-intensive ICE regimen permitted dose escalation of ifosfamide with a mean interval of 16-17 days. We conclude this regimen is well tolerated, with acceptable hematological and non-hematological toxicity.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"94977","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Yoshizawa, Hirohisa"}]},{"nameIdentifiers":[{"nameIdentifier":"94978","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Matsumoto, Naoya"}]},{"nameIdentifiers":[{"nameIdentifier":"94979","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Mochizuki, Hiroshi"}]},{"nameIdentifiers":[{"nameIdentifier":"94980","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Kuriyama, Hideyuki"}]},{"nameIdentifiers":[{"nameIdentifier":"94981","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Kagamu, Hiroshi"}]},{"nameIdentifiers":[{"nameIdentifier":"94982","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Suzuki, Eiichi"}]},{"nameIdentifiers":[{"nameIdentifier":"94983","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Gejyo, Fumitake"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"吉澤, 弘久"}],"nameIdentifiers":[{"nameIdentifier":"94970","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"松本, 尚也"}],"nameIdentifiers":[{"nameIdentifier":"94971","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"望月, 博史"}],"nameIdentifiers":[{"nameIdentifier":"94972","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"栗山, 英之"}],"nameIdentifiers":[{"nameIdentifier":"94973","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"各務, 博"}],"nameIdentifiers":[{"nameIdentifier":"94974","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鈴木, 栄一"}],"nameIdentifiers":[{"nameIdentifier":"94975","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"下条, 文武"}],"nameIdentifiers":[{"nameIdentifier":"94976","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"115(9)_432-437.pdf","filesize":[{"value":"1.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"115(9)_432-437.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/14723/files/115(9)_432-437.pdf"},"version_id":"800a2eeb-27ec-4133-a576-034f245cb1b1"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Small cell lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"Dose intensive chemotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"Granulocyte Colony-Stimulating Factor","subitem_subject_scheme":"Other"},{"subitem_subject":"Hematopoietic Stem Cell Transplantation","subitem_subject_scheme":"Other"},{"subitem_subject":"Leukapheresis","subitem_subject_scheme":"Other"},{"subitem_subject":"小細胞肺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"高用量化学療法","subitem_subject_scheme":"Other"},{"subitem_subject":"顆粒球コロニー刺激因子","subitem_subject_scheme":"Other"},{"subitem_subject":"造血幹細胞移植","subitem_subject_scheme":"Other"},{"subitem_subject":"幹細胞採取","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"2）小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"2）小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)"},{"subitem_title":"2）小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1071"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-11-09"},"publish_date":"2017-11-09","publish_status":"0","recid":"14723","relation_version_is_last":true,"title":["2）小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:46:39.500714+00:00"}